Revance to Participate in Upcoming Investor Conferences

February 23, 2016

NEWARK, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will be participating in two upcoming investor conferences.

Revance management is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Tuesday, March 8 at 10:00am ET.

Revance management is also scheduled to present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15 at 11:15am ET.

Interested parties can access the live audio webcast for both of these conference presentations from the investor relations section of the company's website at The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin drug products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001) and DaxibotulinumtoxinA RT002 for Injection (RT002), in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at

"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.



Revance TherapeuticsJeanie Herbert

(714) 325-3584

Westwicke PartnersLeigh Salvo

(415) 513-1281

Trade Media:

Nadine Tosk

(847) 920-9858

Source: Revance Therapeutics, Inc

News Provided by Acquire Media